Display options
Cite
Kumar A, Darcis G, Van Lint C, et al. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics. 2015;7:103doi: 10.1186/s13148-015-0137-6.
Kumar, A., Darcis, G., Van Lint, C., & Herbein, G. (2015). Epigenetic control of HIV-1 post integration latency: implications for therapy. Clinical epigenetics, 7103. https://doi.org/10.1186/s13148-015-0137-6
Kumar, Amit, et al. "Epigenetic control of HIV-1 post integration latency: implications for therapy." Clinical epigenetics vol. 7 (2015): 103. doi: https://doi.org/10.1186/s13148-015-0137-6
Kumar A, Darcis G, Van Lint C, Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015. PMID: 26405463; PMCID: PMC4581042.
Copy Download .nbib Format: NLM
Share it on

Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015.

Epigenetic control of HIV-1 post integration latency: implications for therapy.

Clinical epigenetics

Amit Kumar, Gilles Darcis, Carine Van Lint, Georges Herbein

Affiliations

  1. Department of Virology, Pathogens & Inflammation Laboratory, University of Franche-Comté and COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon, Hôpital Saint-Jacques, 2 place Saint-Jacques, F-25030 Besançon cedex, France.
  2. Service of Molecular Virology, Institute of Molecular Biology and Medicine, Université Libre de Bruxelles (ULB), 12 Rue des Profs Jeener et Brachet, 6041 Gosselies, Belgium.

PMID: 26405463 PMCID: PMC4581042 DOI: 10.1186/s13148-015-0137-6

Abstract

With the development of effective combined anti-retroviral therapy (cART), there is significant reduction in deaths associated with human immunodeficiency virus type 1 (HIV-1) infection. However, the complete cure of HIV-1 infection is difficult to achieve without the elimination of latent reservoirs which exist in the infected individuals even under cART regimen. These latent reservoirs established during early infection have long life span, include resting CD4(+) T cells, macrophages, central nervous system (CNS) resident macrophage/microglia, and gut-associated lymphoid tissue/macrophages, and can actively produce virus upon interruption of the cART. Several epigenetic and non-epigenetic mechanisms have been implicated in the regulation of viral latency. Epigenetic mechanisms such as histone post translational modifications (e.g., acetylation and methylation) and DNA methylation of the proviral DNA and microRNAs are involved in the establishment of HIV-1 latency. The better understanding of epigenetic mechanisms modulating HIV-1 latency could give clues for the complete eradication of these latent reservoirs. Several latency-reversing agents (LRA) have been found effective in reactivating HIV-1 reservoirs in vitro, ex vivo, and in vivo. Some of these agents target epigenetic modifications to elicit viral expression in order to kill latently infected cells through viral cytopathic effect or host immune response. These therapeutic approaches aimed at achieving a sterilizing cure (elimination of HIV-1 from the human body). In the present review, we will discuss our current understanding of HIV-1 epigenomics and how this information can be moved from the laboratory bench to the patient's bedside.

Keywords: CD4+ T cells; Epigenetics; HIV-1; Histone modifications; Latency; MicroRNAs; Microglia; Monocyte/macrophage

References

  1. Front Immunol. 2015 Feb 04;6:29 - PubMed
  2. Drug Discov Today. 2013 Jun;18(11-12):541-51 - PubMed
  3. Cell Host Microbe. 2008 Aug 14;4(2):134-46 - PubMed
  4. Curr HIV/AIDS Rep. 2015 Mar;12(1):88-96 - PubMed
  5. EMBO J. 2003 Dec 15;22(24):6550-61 - PubMed
  6. J Virol. 2011 Jun;85(12):6060-4 - PubMed
  7. J Leukoc Biol. 2012 Dec;92(6):1147-54 - PubMed
  8. Cell Host Microbe. 2008 Mar 13;3(3):158-67 - PubMed
  9. Clin Infect Dis. 2014 Mar;58(6):883-90 - PubMed
  10. J Acquir Immune Defic Syndr. 2010 May 1;54(1):1-9 - PubMed
  11. J Biol Chem. 2015 May 29;290(22):13736-48 - PubMed
  12. Curr Opin HIV AIDS. 2011 Jan;6(1):25-9 - PubMed
  13. EMBO J. 1993 Aug;12(8):3249-59 - PubMed
  14. J Neurovirol. 2015 Jun;21(3):222-6 - PubMed
  15. Cell Cycle. 2013 Feb 1;12 (3):452-62 - PubMed
  16. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34 - PubMed
  17. Lancet HIV. 2014 Oct;1(1):e13-21 - PubMed
  18. J Virol. 2012 May;86(9):5390-2 - PubMed
  19. EMBO J. 2002 Dec 2;21(23):6539-48 - PubMed
  20. Nature. 2015 May 14;521(7551):227-31 - PubMed
  21. PLoS One. 2014 Aug 19;9(8):e102684 - PubMed
  22. Nat Commun. 2015 Mar 06;6:6483 - PubMed
  23. J Infect Dis. 2010 Nov 15;202(10):1553-61 - PubMed
  24. J Infect Dis. 2015 Nov 1;212(9):1345-7 - PubMed
  25. J Infect Dis. 2008 Mar 1;197(5):714-20 - PubMed
  26. Nucleic Acids Res. 2012 Jan;40(1):414-27 - PubMed
  27. Retrovirology. 2014 Dec 09;11:108 - PubMed
  28. Biochem J. 2003 Mar 15;370(Pt 3):737-49 - PubMed
  29. PLoS Pathog. 2014 Nov 13;10(10):e1004473 - PubMed
  30. Curr Opin Infect Dis. 2014 Feb;27(1):29-35 - PubMed
  31. PLoS One. 2011 Apr 05;6(4):e18270 - PubMed
  32. Nat Med. 2014 Apr;20(4):425-9 - PubMed
  33. Genes Dev. 2007 Jul 15;21(14):1767-78 - PubMed
  34. J Virol. 2011 Jun;85(11):5384-93 - PubMed
  35. Biosystems. 2010 Aug;101(2):88-96 - PubMed
  36. Nature. 2012 Jul 25;487(7408):482-5 - PubMed
  37. J Biol Chem. 2010 May 28;285(22):16538-45 - PubMed
  38. Int J Mol Med. 2010 Aug;26(2):265-72 - PubMed
  39. PLoS One. 2014 Nov 19;9(11):e113341 - PubMed
  40. Cell. 2002 Aug 23;110(4):521-9 - PubMed
  41. PLoS Biol. 2005 Feb;3(2):e41 - PubMed
  42. Retrovirology. 2009 Jun 02;6:52 - PubMed
  43. EMBO J. 1996 Mar 1;15(5):1112-20 - PubMed
  44. J Med Virol. 1997 Jun;52(2):179-89 - PubMed
  45. Retrovirology. 2012 May 03;9:37 - PubMed
  46. Blood. 2009 Jan 15;113(3):671-4 - PubMed
  47. Viruses. 2015 Mar 31;7(4):1578-98 - PubMed
  48. PLoS Pathog. 2011 Mar;7(3):e1001313 - PubMed
  49. Viruses. 2014 Apr 22;6(4):1837-60 - PubMed
  50. EMBO J. 2007 Jan 24;26(2):412-23 - PubMed
  51. AIDS. 2014 Aug 24;28(13):1945-56 - PubMed
  52. Cold Spring Harb Perspect Biol. 2014 May 01;6(5):a019133 - PubMed
  53. J Med Chem. 2008 Mar 27;51(6):1505-29 - PubMed
  54. J Biol Chem. 2011 Jun 24;286(25):22211-8 - PubMed
  55. PLoS One. 2012;7(11):e48832 - PubMed
  56. PLoS Pathog. 2011 May;7(5):e1002060 - PubMed
  57. J Acquir Immune Defic Syndr. 2006 Sep;43(1):65-8 - PubMed
  58. AIDS. 2010 Feb 20;24(4):609-11 - PubMed
  59. J Clin Psychopharmacol. 2006 Jun;26(3):290-302 - PubMed
  60. J Virol. 2015 Aug;89(16):8392-405 - PubMed
  61. PLoS One. 2009 Jun 30;4(6):e6093 - PubMed
  62. AIDS Res Hum Retroviruses. 2006 Sep;22(9):854-64 - PubMed
  63. BMC Mol Biol. 2007 Jul 30;8:63 - PubMed
  64. Immunology. 2010 May;130(1):1-9 - PubMed
  65. Retrovirology. 2004 Dec 15;1:43 - PubMed
  66. J Biol Chem. 2007 May 4;282(18):13141-5 - PubMed
  67. EMBO J. 2004 Jun 16;23(12):2369-80 - PubMed
  68. Science. 2007 Mar 16;315(5818):1579-82 - PubMed
  69. J Biol Chem. 2004 Oct 1;279(40):42008-17 - PubMed
  70. FASEB J. 2012 Nov;26(11):4755-64 - PubMed
  71. J Biomol Screen. 2012 Jan;17(1):2-17 - PubMed
  72. PLoS Pathog. 2009 Aug;5(8):e1000554 - PubMed
  73. J Biol Chem. 2009 Mar 13;284(11):6782-9 - PubMed
  74. Hum Vaccin Immunother. 2013 May;9(5):993-1001 - PubMed
  75. AIDS. 2013 Nov 28;27(18):2853-62 - PubMed
  76. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):1-7 - PubMed
  77. J Virol. 2011 Apr;85(7):3187-202 - PubMed
  78. Curr Opin HIV AIDS. 2014 Nov;9(6):552-8 - PubMed
  79. Mol Biol Rep. 2011 Nov;38(8):5071-8 - PubMed
  80. J Virol. 2004 Jun;78(12):6122-33 - PubMed
  81. AIDS. 2013 Jan 14;27(2):F7-F11 - PubMed
  82. Mol Ther. 2006 Aug;14(2):218-25 - PubMed
  83. J Mol Biol. 2014 Mar 20;426(6):1178-97 - PubMed
  84. PLoS One. 2015 Apr 13;10(4):e0119234 - PubMed
  85. Nucleic Acids Res. 2005 Apr 22;33(7):2318-31 - PubMed
  86. PLoS Pathog. 2015 Jul 30;11(7):e1005063 - PubMed
  87. Nucleic Acids Res. 2013 Jan 7;41(1):277-87 - PubMed
  88. Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400 - PubMed
  89. J Mol Biol. 2015 Feb 13;427(3):688-94 - PubMed
  90. Curr Opin HIV AIDS. 2013 Mar;8(2):87-92 - PubMed
  91. PLoS Pathog. 2009 Jan;5(1):e1000263 - PubMed
  92. AIDS. 2012 Jul 31;26(12):1473-82 - PubMed
  93. Curr Opin HIV AIDS. 2013 Jul;8(4):318-25 - PubMed
  94. Nat Rev Microbiol. 2014 Nov;12(11):750-64 - PubMed
  95. HIV Med. 2012 May;13(5):291-6 - PubMed
  96. J Virol. 2012 Mar;86(6):3244-52 - PubMed
  97. AIDS. 2015 Jun 19;29(10):1147-59 - PubMed
  98. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14 - PubMed
  99. Retrovirology. 2010 Apr 09;7:32 - PubMed
  100. J Biol Chem. 2011 Nov 25;286(47):41125-34 - PubMed
  101. PLoS Pathog. 2009 Jun;5(6):e1000495 - PubMed
  102. Retrovirology. 2014 Jul 01;11:50 - PubMed
  103. Nature. 2012 Jul 25;487(7408):439-40 - PubMed
  104. Blood. 2013 May 23;121(21):4321-9 - PubMed
  105. Epigenomics. 2014;6(5):533-46 - PubMed
  106. J Leukoc Biol. 2003 Nov;74(5):736-49 - PubMed
  107. FEBS Lett. 2011 Nov 16;585(22):3549-54 - PubMed
  108. Nucleic Acids Res. 2012 Oct;40(18):9160-70 - PubMed
  109. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096 - PubMed
  110. Virol J. 2010 Oct 13;7:266 - PubMed
  111. Mol Oncol. 2012 Dec;6(6):657-82 - PubMed
  112. Science. 2001 Aug 31;293(5535):1653-7 - PubMed
  113. Cell Host Microbe. 2008 Aug 14;4(2):123-33 - PubMed
  114. J Virol. 2015 Oct;89(20):10176-89 - PubMed
  115. Retrovirology. 2004 Dec 15;1:44 - PubMed
  116. Curr HIV Res. 2011 Dec 1;9(8):554-67 - PubMed
  117. Retrovirology. 2013 Jun 26;10:67 - PubMed
  118. J Leukoc Biol. 2003 Nov;74(5):642-9 - PubMed
  119. Retrovirology. 2010 Apr 07;7:30 - PubMed
  120. Mol Cell Ther. 2014 Apr 02;2:10 - PubMed
  121. Nucleic Acids Res. 2008 Apr;36(7):2353-65 - PubMed
  122. Nat Med. 2005 Dec;11(12):1287-9 - PubMed
  123. Microbiol Mol Biol Rev. 2006 Sep;70(3):646-59 - PubMed
  124. Rev Med Virol. 2015 Sep;25(5):320-41 - PubMed
  125. Epigenomics. 2011 Aug;3(4):487-502 - PubMed
  126. PLoS Pathog. 2014 Apr 10;10(4):e1004071 - PubMed
  127. Pharmacol Ther. 2014 Sep;143(3):323-36 - PubMed
  128. EMBO J. 2006 Jan 11;25(1):139-49 - PubMed
  129. J Virol. 2011 Sep;85(17 ):9078-89 - PubMed
  130. AIDS Rev. 2012 Jul-Sep;14(3):188-94 - PubMed
  131. Brain Pathol. 2002 Oct;12(4):442-55 - PubMed
  132. Retrovirology. 2009 Dec 04;6:111 - PubMed
  133. Microbes Infect. 2015 Sep;17(9):651-9 - PubMed
  134. Antimicrob Agents Chemother. 2015 Jul;59(7):3984-94 - PubMed
  135. Ann Neurol. 2009 Aug;66(2):253-8 - PubMed
  136. AIDS. 2014 Jul 17;28(11):1555-66 - PubMed
  137. AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12 - PubMed
  138. J Virol. 2008 Dec;82(24):12291-303 - PubMed
  139. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13690-5 - PubMed
  140. Acta Pharmacol Sin. 2015 Aug;36(8):908-16 - PubMed
  141. EMBO J. 2007 Jan 24;26(2):424-35 - PubMed
  142. PLoS Pathog. 2013 Feb;9(2):e1003174 - PubMed
  143. J Virol. 2007 Nov;81(22):12218-26 - PubMed
  144. J Infect Dis. 2013 Oct 15;208(8):1212-20 - PubMed
  145. J Theor Biol. 2012 Oct 7;310:14-20 - PubMed
  146. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):E2284-93 - PubMed
  147. Retrovirology. 2015 Feb 12;12:16 - PubMed
  148. Trends Genet. 2005 Jun;21(6):339-45 - PubMed
  149. AIDS Res Hum Retroviruses. 2004 May;20(5):497-505 - PubMed

Publication Types